BEYONTTRA: Uses, Dosage & Side Effects
A transthyretin (TTR) stabilizer for the treatment of cardiomyopathy caused by transthyretin amyloidosis (ATTR-CM) in adults
BEYONTTRA (acoramidis) is a prescription medication used to treat adults with cardiomyopathy caused by transthyretin amyloidosis (ATTR-CM). In this progressive and potentially life-threatening condition, a protein called transthyretin (TTR) becomes unstable, breaks apart, misfolds, and deposits as amyloid fibrils in the heart muscle, causing it to stiffen and impair cardiac function. BEYONTTRA stabilizes the TTR protein in its normal four-unit (tetrameric) structure, preventing it from dissociating and forming harmful amyloid. It is taken as an oral tablet twice daily and represents an important treatment option for patients living with this serious cardiac disease.
Quick Facts: BEYONTTRA
Key Takeaways
- BEYONTTRA (acoramidis) is a transthyretin stabilizer that prevents the TTR protein from breaking apart and forming harmful amyloid deposits in the heart, slowing the progression of transthyretin amyloid cardiomyopathy (ATTR-CM).
- The recommended dose is two 356 mg tablets (712 mg) taken by mouth twice daily, with or without food, for a total daily dose of 1424 mg. Tablets should be swallowed whole with water.
- The most common side effects are diarrhea and gout (painful joint inflammation), both of which occur in more than 1 in 10 patients. BEYONTTRA may also cause changes in blood tests for kidney and thyroid function that are not considered harmful.
- Patients should not stop taking BEYONTTRA without consulting their doctor, as discontinuation may lead to worsening of the underlying cardiac condition.
- BEYONTTRA is manufactured by Bayer AG and has been approved by the European Medicines Agency (EMA) and other regulatory authorities for the treatment of ATTR-CM in adult patients.
What Is BEYONTTRA and What Is It Used For?
BEYONTTRA contains the active substance acoramidis (as hydrochloride). It belongs to a class of medications known as transthyretin (TTR) stabilizers, which represent a targeted therapeutic approach to one of the most important causes of infiltrative cardiomyopathy in older adults. BEYONTTRA was developed to address the underlying molecular pathology of transthyretin amyloid cardiomyopathy (ATTR-CM), a condition in which the heart muscle becomes progressively stiffer and less able to function normally due to the accumulation of misfolded protein.
Transthyretin (TTR) is a transport protein produced primarily by the liver that normally circulates in the blood as a stable four-unit structure called a tetramer. Its physiological roles include transporting thyroid hormone (thyroxine) and retinol (vitamin A, via retinol-binding protein) throughout the body. Under normal circumstances, the TTR tetramer remains intact and performs these functions without issue. However, in certain individuals, the TTR tetramer becomes destabilized and begins to dissociate into individual protein units (monomers). Once separated, these monomers can misfold into abnormal configurations and aggregate into insoluble fibrous deposits known as amyloid fibrils.
When amyloid fibrils accumulate in the heart muscle (myocardium), the condition is called transthyretin amyloid cardiomyopathy (ATTR-CM). The deposited amyloid causes the heart walls to become thickened and stiff, impairing the heart's ability to fill with blood properly (a condition known as restrictive cardiomyopathy) and ultimately reducing its pumping capacity. Patients with ATTR-CM commonly experience symptoms of heart failure, including shortness of breath, fatigue, fluid retention (swelling in the legs and abdomen), and exercise intolerance. Without treatment, the condition is progressive and is associated with significant morbidity and reduced survival.
ATTR-CM exists in two main forms. Wild-type ATTR-CM (wtATTR-CM), previously known as senile systemic amyloidosis, occurs predominantly in older men (typically over 65 years of age) without any genetic mutation in the TTR gene. It is increasingly recognized as an underdiagnosed cause of heart failure with preserved ejection fraction (HFpEF) in the elderly population. Hereditary ATTR-CM (hATTR-CM), also called variant ATTR amyloidosis, is caused by specific inherited mutations in the TTR gene that make the protein less stable. More than 130 different TTR gene mutations have been identified worldwide, with varying geographic and ethnic distributions. Both forms result in the same basic pathology: deposition of TTR-derived amyloid in the heart.
BEYONTTRA works by binding with high selectivity and affinity to the thyroxine-binding sites on the TTR tetramer. By occupying these sites, acoramidis acts as a molecular wedge that holds the four subunits of TTR together, preventing the tetramer from dissociating into its component monomers. This stabilization of the native TTR structure is the critical therapeutic mechanism: if the tetramer cannot fall apart, the monomers that would otherwise misfold and form amyloid are never generated. Clinical studies have demonstrated that BEYONTTRA achieves near-complete stabilization of TTR at therapeutic doses, which translates into a significant reduction in new amyloid formation and deposition.
The pivotal ATTRibute-CM clinical trial evaluated the efficacy and safety of acoramidis in patients with ATTR-CM (both wild-type and hereditary forms). The trial demonstrated that treatment with BEYONTTRA resulted in significant reductions in all-cause mortality and cardiovascular hospitalizations compared with placebo, along with improvements in functional capacity and quality of life. These results established BEYONTTRA as an effective disease-modifying therapy for ATTR-CM and led to its regulatory approval.
Amyloidosis is a group of diseases in which abnormal proteins (amyloid) accumulate in organs and tissues. Transthyretin amyloidosis is just one type, but it is one of the most common forms affecting the heart. Advances in diagnostic techniques, including bone scintigraphy and cardiac MRI, have made it possible to identify ATTR-CM without invasive biopsy in many cases, leading to increased diagnosis rates worldwide. Early diagnosis and treatment initiation are important because the disease is progressive and existing amyloid deposits are difficult to remove once formed.
What Should You Know Before Taking BEYONTTRA?
Contraindications
BEYONTTRA should not be taken by individuals who have a known allergy (hypersensitivity) to acoramidis or to any of the excipients contained in the formulation. Allergic reactions to medications can range from mild skin reactions to more severe responses, and it is important to review the full list of ingredients before starting treatment. If you have previously experienced an allergic reaction to any component of BEYONTTRA, inform your doctor immediately.
As with all medications, if you experience signs of a severe allergic reaction after taking BEYONTTRA – such as difficulty breathing, swelling of the face or throat, widespread rash, or a rapid heartbeat – seek medical attention immediately and do not take any further doses until you have consulted your healthcare provider.
Warnings and Precautions
Before beginning treatment with BEYONTTRA, speak with your doctor, pharmacist, or nurse about your complete medical history. There are several important considerations that your healthcare team should be aware of:
- Liver problems: If you have any form of liver disease or impaired liver function, inform your doctor before starting BEYONTTRA. The liver is the primary site of TTR production, and liver function may influence how the medication works in your body. Your doctor may need to monitor your liver function more closely during treatment.
- Severe kidney problems: If you have severe kidney impairment, discuss this with your doctor before treatment. While BEYONTTRA is not primarily eliminated by the kidneys, patients with severe renal impairment may need additional monitoring.
- Changes in kidney function tests: When starting BEYONTTRA, you may notice changes in blood tests that measure kidney function, such as serum creatinine levels and estimated glomerular filtration rate (eGFR). These changes are thought to result from the drug’s effect on how creatinine is handled in the body rather than from actual kidney damage. It is important that your doctor is aware you are taking BEYONTTRA when interpreting these laboratory results, so that unnecessary concern or additional testing can be avoided.
- Changes in thyroid function tests: BEYONTTRA can also cause changes in blood tests that measure thyroid function. Because the drug binds to the thyroxine-binding sites on TTR, it may alter the distribution and measurement of thyroid hormones in the blood. These laboratory changes are not expected to cause clinical thyroid dysfunction (i.e., they should not make you feel unwell or cause symptoms of thyroid disease). Nevertheless, inform any doctor who orders thyroid function tests that you are taking BEYONTTRA.
BEYONTTRA may affect certain blood test results. Always inform your healthcare provider and laboratory technicians that you are taking this medication before having blood tests, particularly those measuring kidney function (creatinine, eGFR) and thyroid function (T4, TSH). The changes observed are drug-related effects on the assays, not indicators of organ damage.
Children and Adolescents
BEYONTTRA has not been studied in children and adolescents and is not intended for use in this age group. Transthyretin amyloid cardiomyopathy is predominantly a disease of adults, and the safety and effectiveness of acoramidis in pediatric patients have not been established. If you have questions about the use of this medication in younger individuals, discuss them with your healthcare provider.
Other Medications
Inform your doctor or pharmacist about all medications you are currently taking, have recently taken, or might take, including over-the-counter medications, herbal supplements, and vitamins. While BEYONTTRA does not have a large number of established drug interactions, it is important for your healthcare team to have a complete picture of your medication regimen. Some medications may be affected by concurrent use of acoramidis, and your doctor can advise you on whether any adjustments are needed.
Patients with ATTR-CM often take multiple medications for heart failure and related conditions, including diuretics, beta-blockers, and anticoagulants. Your doctor will carefully consider any potential interactions when prescribing BEYONTTRA alongside your existing treatment regimen.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, or are planning to become pregnant, consult your doctor or pharmacist before using BEYONTTRA. The effects of acoramidis on the developing fetus are not known, as there are no adequate clinical data on the use of this medication in pregnant women. As a precautionary measure, it is generally recommended that BEYONTTRA be avoided during pregnancy unless the potential benefit to the mother is judged to outweigh the potential risk to the unborn child.
It is not known whether acoramidis or its metabolites pass into breast milk. If you are breastfeeding or planning to breastfeed, discuss this with your doctor before starting treatment. A decision should be made whether to discontinue breastfeeding or to discontinue BEYONTTRA therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother.
Driving and Operating Machinery
BEYONTTRA is not expected to have any significant effect on your ability to drive vehicles or operate machinery. In clinical trials, no impairment of cognitive function, coordination, or alertness was attributed to the medication. However, if you experience any side effects that could affect your ability to drive or operate machinery safely, you should refrain from these activities until the symptoms resolve.
Important Information About Ingredients
Each BEYONTTRA tablet contains acoramidis hydrochloride equivalent to 356 mg of acoramidis. The tablet also contains several inactive ingredients (excipients), including microcrystalline cellulose, croscarmellose sodium, colloidal hydrated silica, magnesium stearate, and various coating agents. Importantly, each tablet contains less than 1 mmol of sodium (23 mg), meaning it is essentially sodium-free. This is relevant for patients who are on a sodium-restricted diet, which is common among individuals with heart failure.
How Does BEYONTTRA Interact with Other Drugs?
Drug interaction data for BEYONTTRA are still being characterized as clinical experience with acoramidis grows. Because the drug binds to the thyroxine-binding sites on TTR, it has the potential to affect the distribution of endogenous thyroid hormones and may interfere with certain laboratory assays. Beyond this, acoramidis may interact with drug-metabolizing enzymes and transporter proteins. The most important considerations are outlined below.
It is essential to tell your doctor about all medications you are taking, including prescription drugs, over-the-counter medications, and dietary supplements. Patients with ATTR-CM typically have multiple comorbidities and take several medications concurrently, so a thorough medication review is an important part of initiating BEYONTTRA therapy.
Potential Interactions
| Interacting Drug / Class | Effect | Clinical Significance |
|---|---|---|
| Strong CYP2C8 inhibitors (e.g., gemfibrozil) | May increase acoramidis plasma levels | Use with caution; dose adjustments may be considered |
| BCRP substrates (e.g., rosuvastatin, sulfasalazine) | Acoramidis may inhibit BCRP transporter, increasing substrate levels | Monitor for increased effects/toxicity of BCRP substrates |
| OATP1B1/1B3 substrates (e.g., statins, repaglinide) | Potential inhibition of hepatic uptake transporters | Monitor for increased effects of statin therapy; discuss with doctor |
| Thyroid function tests | Changes in measured thyroid hormone levels due to TTR binding | Not clinically significant; inform lab of BEYONTTRA use |
| Kidney function tests (creatinine, eGFR) | Apparent decrease in eGFR / increase in creatinine | Drug effect on assay, not true renal damage; inform clinician |
Heart Failure Medications
Patients with ATTR-CM are typically prescribed a variety of heart failure therapies, and BEYONTTRA has been studied alongside many of these. In clinical trials, acoramidis was used concomitantly with diuretics, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), mineralocorticoid receptor antagonists, and anticoagulants. No significant adverse interactions between BEYONTTRA and these standard heart failure medications were identified. However, the overall treatment plan should always be coordinated by your cardiologist, who can make informed decisions about medication combinations.
If you are taking tafamidis (another TTR stabilizer), discuss with your doctor before switching to or adding BEYONTTRA, as both drugs target the same binding sites on the TTR protein. Concurrent use of two TTR stabilizers is generally not recommended, and transitioning from one to another should be done under medical supervision.
Because patients with ATTR-CM often take multiple medications for heart failure and related conditions, a comprehensive medication review should be conducted when starting BEYONTTRA. Bring a complete list of all medications, including supplements, to each appointment so your healthcare team can monitor for interactions and optimize your overall treatment plan.
What Is the Correct Dosage of BEYONTTRA?
Always take BEYONTTRA exactly as your doctor or pharmacist has instructed. If you are uncertain about any aspect of your dosing regimen, consult your healthcare provider for clarification. The dosing of BEYONTTRA is straightforward and does not require adjustment based on body weight, making it a fixed-dose oral therapy suitable for long-term use at home.
Adults
Standard Adult Dose
Dose: Two 356 mg film-coated tablets (712 mg) taken orally twice daily
Total Daily Dose: 1424 mg (four tablets per day)
Administration: Swallow tablets whole with water. Do not crush, break, or chew the tablets.
Timing: Take one dose in the morning and one dose in the evening. Can be taken with or without food.
Duration: BEYONTTRA is intended for long-term, continuous treatment. Continue taking it as prescribed for as long as your doctor recommends.
| Patient Group | Dose per Administration | Frequency | Total Daily Dose |
|---|---|---|---|
| Adults | 712 mg (2 tablets) | Twice daily | 1424 mg (4 tablets) |
| Elderly (≥65 years) | 712 mg (2 tablets) | Twice daily | 1424 mg (4 tablets) |
| Mild/moderate kidney impairment | 712 mg (2 tablets) | Twice daily | 1424 mg (4 tablets) |
| Severe kidney impairment | Consult doctor | As directed | As directed |
| Liver impairment | Consult doctor | As directed | As directed |
| Children and adolescents | Not recommended | N/A | N/A |
Elderly Patients
No dose adjustment is required for elderly patients. ATTR-CM is predominantly a disease of older adults, and the majority of patients enrolled in clinical trials were over 65 years of age. The safety and efficacy profile observed in older patients was consistent with the overall study population. However, elderly patients may have additional comorbidities and concomitant medications that require careful clinical oversight.
Missed Dose
If you forget to take a dose of BEYONTTRA, take your tablets at the next regularly scheduled time. Do not take a double dose to make up for a missed one. Consistent adherence to the twice-daily dosing schedule is important to maintain stable TTR stabilization and maximize the therapeutic benefit of the medication. If you frequently forget doses, consider setting reminders or using a pill organizer to help maintain your schedule.
Overdose
Do not take more tablets than your doctor has prescribed. If you believe you have accidentally taken too much BEYONTTRA, contact your doctor or go to your nearest emergency department immediately. Bring the medication packaging with you so that healthcare professionals can identify the product and the amount taken. In clinical development, limited data are available on overdose, and treatment would be supportive based on symptoms.
Stopping Treatment
Do not stop taking BEYONTTRA without first talking to your doctor. If you discontinue treatment, the stabilization of transthyretin will cease, and the process of amyloid formation and deposition may resume. This could lead to worsening of your cardiac condition. If you have concerns about your treatment, discuss them with your cardiologist.
BEYONTTRA is designed for long-term use, and its benefits depend on continuous, sustained stabilization of the TTR protein. If treatment is stopped, TTR will gradually return to its unstabilized state, allowing amyloid fibrils to form again. Patients who discontinue therapy may experience a decline in cardiac function over time. Always consult your doctor before making any changes to your medication regimen.
What Are the Side Effects of BEYONTTRA?
Like all medicines, BEYONTTRA can cause side effects, although not everyone experiences them. The side effect profile of acoramidis has been established through large-scale clinical trials involving patients with ATTR-CM, who are typically older adults with significant underlying cardiovascular disease. In the ATTRibute-CM trial, the overall incidence of adverse events was similar between the acoramidis and placebo groups, suggesting that many reported events may be related to the underlying disease rather than the medication itself.
It is important to report any new or worsening symptoms to your healthcare provider, even if they are not listed below. Post-marketing surveillance continues to monitor the safety of BEYONTTRA as it is used by a broader patient population.
Very Common
May affect more than 1 in 10 people
- Diarrhea – Loose or watery stools. Usually mild to moderate in severity and often resolves with continued treatment. If diarrhea is persistent or severe, contact your doctor, as dehydration can be a concern in patients with heart failure.
- Gout (painful inflammation of the joints) – Caused by the buildup of uric acid crystals in the joints. Gout typically presents as sudden, severe pain and swelling in a joint, most commonly the big toe. Your doctor may prescribe additional medication to manage gout symptoms or prevent flare-ups.
Reported in Clinical Trials
Additional observations from clinical studies
- Changes in kidney function tests – Increases in serum creatinine and decreases in estimated glomerular filtration rate (eGFR) may be observed. These are attributed to the drug’s effect on creatinine handling rather than actual kidney injury.
- Changes in thyroid function tests – Alterations in measured thyroid hormone levels (T4, T3) may occur due to the drug’s interaction with TTR’s thyroxine-binding function. These changes are not expected to cause clinical thyroid symptoms.
The overall safety profile of BEYONTTRA in clinical trials was favorable, with a low rate of treatment discontinuation due to adverse events. The most frequently reported side effects – diarrhea and gout – are generally manageable with supportive care and do not typically require stopping the medication. Serious adverse events were uncommon and occurred at similar rates in the treatment and placebo groups.
Because ATTR-CM predominantly affects older adults who often have other medical conditions, it can sometimes be difficult to distinguish between side effects of the medication and symptoms of the underlying disease or comorbidities. If you experience any new or unusual symptoms after starting BEYONTTRA, it is always best to discuss them with your doctor so that the cause can be properly evaluated.
Reporting Side Effects
Reporting suspected side effects after a medicine has been authorized is important. It allows continuous monitoring of the medicine’s benefit-risk balance. Healthcare professionals and patients are encouraged to report any suspected adverse reactions through their national pharmacovigilance system. In the European Union, reports can be submitted through the national reporting systems listed on the European Medicines Agency website. In the United States, reports can be made to the FDA MedWatch program.
How Should You Store BEYONTTRA?
Proper storage of medications is essential to maintain their effectiveness and safety. BEYONTTRA 356 mg film-coated tablets do not require any special storage conditions. The tablets should be kept at room temperature and do not need to be refrigerated. Store them in their original packaging to protect from environmental factors.
Keep BEYONTTRA out of the sight and reach of children. Accidental ingestion by children can be dangerous and requires immediate medical attention. Use the expiry date printed on the carton (after “EXP”) to determine when the medication should no longer be used. The expiry date refers to the last day of the indicated month.
Do not dispose of medications by flushing them down the toilet or throwing them in household waste. These methods can be harmful to the environment. Instead, return any unused or expired BEYONTTRA tablets to your pharmacy, where they will be disposed of safely according to local regulations. Many pharmacies and healthcare facilities have take-back programs specifically designed for the safe disposal of unused medications.
What Does BEYONTTRA Contain?
Active Ingredient
The active substance in each BEYONTTRA tablet is acoramidis hydrochloride, equivalent to 356 mg of acoramidis. Acoramidis is the molecule responsible for the therapeutic effect of stabilizing the transthyretin tetramer, which is the key mechanism in treating ATTR-CM.
Inactive Ingredients (Excipients)
In addition to the active ingredient, BEYONTTRA tablets contain several inactive ingredients that serve various pharmaceutical functions, including maintaining tablet integrity, aiding disintegration, and providing the characteristic appearance of the tablet:
- Tablet core: Microcrystalline cellulose (E 460), croscarmellose sodium (E 468), colloidal hydrated silica (E 551), magnesium stearate (E 470b)
- Film coating: Macrogol-poly(vinyl alcohol)-graft copolymer (E 1209), talc (E 553b), titanium dioxide (E 171), glyceryl monocaprylocaprate type I (E 471), poly(vinyl alcohol) (E 1203), black iron oxide (E 172), propylene glycol (E 1520), hypromellose 2910 (E 464)
As noted in the warnings section, each tablet contains less than 1 mmol (23 mg) of sodium, making it essentially sodium-free. This is an important consideration for patients with heart failure who are often advised to follow a low-sodium diet.
Appearance and Packaging
BEYONTTRA 356 mg film-coated tablets are white, oval-shaped tablets approximately 15 mm long and 7.5 mm wide, with “BEYONTTRA” printed in black ink on one side. The tablets are packaged in dual-chamber PVC/PCTFE blisters with aluminum foil lids, supplied in cartons containing 120 tablets. This pack size is designed to provide a convenient supply for ongoing treatment.
BEYONTTRA is manufactured by Rottendorf Pharma GmbH (Ennigerloh, Germany) and marketed by Bayer AG (Leverkusen, Germany). It has been authorized for sale in the European Union and other countries for the treatment of ATTR-CM in adult patients. Additional information is available from the European Medicines Agency (EMA) at www.ema.europa.eu.
Frequently Asked Questions About BEYONTTRA
BEYONTTRA (acoramidis) is used to treat adults with cardiomyopathy caused by transthyretin amyloidosis (ATTR-CM). In this condition, the transthyretin protein misfolds and deposits as amyloid fibrils in the heart muscle, making it stiff and impairing its function. BEYONTTRA stabilizes the TTR protein to prevent this process, helping to slow the progression of the disease and reduce cardiovascular hospitalizations.
Both BEYONTTRA (acoramidis) and tafamidis are TTR stabilizers used to treat ATTR-CM, but they differ in their binding characteristics. Acoramidis has been shown to achieve near-complete TTR stabilization at therapeutic doses, with higher binding affinity and occupancy of the TTR binding sites. In the ATTRibute-CM trial, BEYONTTRA demonstrated significant reductions in mortality and cardiovascular hospitalizations. The choice between these medications should be made by your cardiologist based on your individual clinical situation.
Yes, BEYONTTRA can be taken with or without food. The tablets should be swallowed whole with water. Taking the medication at the same times each day (morning and evening) can help you maintain a consistent dosing schedule and ensure optimal TTR stabilization throughout the day.
BEYONTTRA can affect certain laboratory measurements without causing actual organ damage. Changes in kidney function tests (creatinine, eGFR) occur because the drug alters how the kidneys handle creatinine, not because it damages the kidneys. Similarly, changes in thyroid function tests occur because acoramidis binds to the same sites on TTR that normally transport thyroid hormones, altering their measured levels in the blood. These are well-characterized effects and should not cause clinical concern, but it is important to inform your healthcare providers that you are taking BEYONTTRA.
If you stop taking BEYONTTRA, the stabilization of your transthyretin protein will gradually wear off, allowing the protein to dissociate and form amyloid deposits again. This can lead to progression of the cardiomyopathy and worsening of heart failure symptoms. Never stop taking BEYONTTRA without consulting your doctor first. If you experience side effects or have concerns about your treatment, discuss them with your healthcare team to find the best approach.
BEYONTTRA is not a cure for transthyretin amyloid cardiomyopathy, but it is a disease-modifying therapy that can slow disease progression. By stabilizing the TTR protein, it prevents the formation of new amyloid deposits. However, it does not remove amyloid that has already accumulated in the heart. Research into therapies that can clear existing amyloid is ongoing. BEYONTTRA represents an important advance in the management of ATTR-CM and has been shown to reduce hospitalizations and improve outcomes.
References & Medical Sources
- European Medicines Agency (EMA). BEYONTTRA (acoramidis) Summary of Product Characteristics. 2025. Available at: www.ema.europa.eu
- U.S. Food and Drug Administration (FDA). BEYONTTRA Prescribing Information. 2024.
- Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018;379(11):1007-1016. doi:10.1056/NEJMoa1805689
- Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42(16):1554-1568. doi:10.1093/eurheartj/ehab072
- Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016;133(24):2404-2412. doi:10.1161/CIRCULATIONAHA.116.021612
- Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73(22):2872-2891. doi:10.1016/j.jacc.2019.04.003
- Writing Committee, Heidenreich PA, Bozkurt B, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2022;79(17):e263-e421. doi:10.1016/j.jacc.2021.12.012
- European Society of Cardiology (ESC). 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44(37):3503-3626.
- World Health Organization (WHO). Model List of Essential Medicines. 23rd List, 2023.
- British National Formulary (BNF). Acoramidis. Available at: bnf.nice.org.uk
Editorial Team
Medical Content
iMedic Medical Editorial Team – Specialists in cardiology, clinical pharmacology, and internal medicine
Medical Review
iMedic Medical Review Board – Independent review according to WHO, EMA, FDA, and ESC guidelines
Evidence Standard
GRADE Framework – Level 1A evidence from systematic reviews and randomized controlled trials
Accessibility
WCAG 2.2 Level AAA – Tested with screen readers, keyboard navigation, and assistive technologies
Last medical review: | Published:
This article is independently produced. iMedic receives no funding from pharmaceutical companies and has no commercial relationships that could influence editorial content. All medical claims are supported by peer-reviewed evidence and international clinical guidelines.